{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GastroEsophageal+Junction+%28GEJ%29+Cancer&page=4", "query": { "condition": "GastroEsophageal Junction (GEJ) Cancer", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 99, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GastroEsophageal+Junction+%28GEJ%29+Cancer&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GastroEsophageal+Junction+%28GEJ%29+Cancer&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T14:53:16.570Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05107674", "title": "A Study of NX-1607 in Adults With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ovarian Cancer, Epithelial", "Gastric Cancer", "GastroEsophageal Junction (GEJ) Cancer", "Head and Neck Squamous Cell Carcinoma", "Metastatic or Unresectable Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Malignant Pleural Mesothelioma (MPM)", "Triple Negative Breast Cancer (TNBC)", "Metastatic Urothelial Carcinoma", "Cervical Cancer", "Diffuse Large B Cell Lymphoma (DLBCL)", "Richter Transformation", "Microsatellite Stable Colorectal Carcinoma" ], "interventions": [ { "name": "NX-1607", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nurix Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 345, "start_date": "2021-09-29", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 10, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05107674" }, { "nct_id": "NCT05891171", "title": "Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Advanced Malignancies", "Bladder Cancer", "Cervical Cancer", "Esophageal Cancer", "Gastric Cancer", "Gastroesophageal-junction Cancer (GEJ)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-Small Cell Lung Cancer (NSCLC)", "Ovarian Cancer", "Renal Cell Carcinoma (RCC)", "Triple Negative Breast Cancer (TNBC)" ], "interventions": [ { "name": "AB598", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-10-13", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Lake City, Florida + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Lake City", "state": "Florida" }, { "city": "Hinsdale", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891171" }, { "nct_id": "NCT00073502", "title": "Phase II Study of Single Agent OSI-7904L in Patients With Gastric or Gastroesophageal (GEJ) Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Adenocarcinoma", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "OSI-7904L", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2003-10", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2006-02-22", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 3, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas • Salt Lake City, Utah", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00073502" }, { "nct_id": "NCT07700420", "title": "Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastro-esophageal Junction (GEJ) Cancer", "Esophagus Cancer" ], "interventions": [ { "name": "PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy", "type": "RADIATION" }, { "name": "FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-08-28", "completion_date": "2031-10-01", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07700420" }, { "nct_id": "NCT07705035", "title": "DBC-664 in Adult Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malignant Germ Cell Tumor", "Lung Adenocarcinoma", "Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma", "Urothelial Carcinoma", "Endometrial Adenocarcinoma", "Ovarian Adenocarcinoma" ], "interventions": [ { "name": "DBC-664", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duboce Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2026-07-17", "completion_date": "2030-04-01", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 6, "location_summary": "Denver, Colorado • Grand Rapids, Michigan • East Brunswick, New Jersey + 3 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "East Brunswick", "state": "New Jersey" }, { "city": "Lake Success", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07705035" }, { "nct_id": "NCT04014075", "title": "DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma Gastric Stage IV With Metastases", "Adenocarcinoma - GEJ" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 79, "start_date": "2019-11-26", "completion_date": "2024-02-13", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 20, "location_summary": "Duarte, California • Los Angeles, California • Monterey, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04014075" }, { "nct_id": "NCT05002127", "title": "A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Gastric Adenocarcinoma" ], "interventions": [ { "name": "Evorpacept (ALX148)", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ALX Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2022-01-15", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 5, "location_summary": "Anaheim, California • Los Angeles, California • Nashville, Tennessee + 2 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Fairfax", "state": "Virginia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05002127" }, { "nct_id": "NCT04492488", "title": "A Study of MRG002 in Patients with HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Advanced or Metastatic Gastric Cancer", "Advanced or Metastatic Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "MRG002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Miracogen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2021-05-24", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 2, "location_summary": "Orange, California • Houston, Texas", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04492488" }, { "nct_id": "NCT07660055", "title": "Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Gastric/Gastroesophageal Junction (GEJ) Cancer", "Bladder Cancer" ], "interventions": [ { "name": "[68Ga]Ga-DWJ155", "type": "DIAGNOSTIC_TEST" }, { "name": "[177Lu]Lu-DWJ155", "type": "DRUG" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2026-06-16", "completion_date": "2032-05-24", "has_results": false, "last_update_posted_date": "2026-08-27", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT07660055" }, { "nct_id": "NCT05207722", "title": "CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic HER2 Positive Gastroesophageal Junction Cancer" ], "interventions": [ { "name": "CYNK-101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Recombinant Human Interleukin-2", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celularity Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1, "start_date": "2022-04-14", "completion_date": "2024-02-15", "has_results": false, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-14T14:53:16.570Z", "location_count": 3, "location_summary": "La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05207722" } ] }